|
|
|
|
||
Re: Cramer am comments> (applicable here and other biotech's)By no means a rocket scientist talking. econdary at $3 Who doesn't want or look for a 300% winner. That diamond in the rough is not obvious in order for it to be a 300% play.. So that means you need to pre-empt the STREET. That is the position that we are in. So are the Institutional INVESTORS and incidentally the insiders. The insiders have a sided advantage. That is why many like to follow insider transactions.. You need to know where the corporation pretty well to really get the gist of the transaction so I don't dwell on this much..Kirk buying 2.8M shares of the secondary spoke volumes even if it were by contract. The key in my opinion has everything to do with the risk/reward ratio. Just look at ZIOP.. If the proof of concept involved in the XON collaboration is a successful one the reward part of the equation is off the chart. Which means the RISK part is the one you should be paying attention to..unless of course if you feel the concept is not attainable. The risk in ZIOP is quite high..At this point you are really just looking at a one trick pony..It is all on the rheo switch. Where some believe you need partnerships to succeed, I am of the opinion that the main way to spread RISK is by increasing the breadth of the pipeline using whatever means available to it. Whether it be stem cell or cart-c or a mesoblast joint venture.. This situation really boils down to the input from Broder, Reed, Frost,Lewis, the consultant whose name escapes me and Kirk to create a business model that produces a revenue stream . I think the reward at the on XON is situation that it makes a 300% move almost low much higher than ZIOP at the present time based on spread of their risk in their business model. Right now I am about 60% ZIOP to 40% XON and increasing to parity.I see both of these stocks as having a decent shot to exceed a 300% move easily. This is based on my circumstances and beliefs. Sold on the Kirk team This is one of those |
return to message board, top of board |